Finerenone

• CAT Number: I006795
• CAS Number: 1050477-31-0
• Molecular Formula: C21H22N4O3
• Molecular Weight: 378.43
• Purity: 98%
• Synonyms: BAY94-8862; BAY 94-8862; BAY-94-8862; BAY948862; BAY 948862; BAY-948862; Finerenone;(4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
• Target: Vitamin D Related/Nuclear Receptor
• Target Protein: P08235
• Solubility: Soluble in DMSO, not in water
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IUPAC Name: (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
• InChI: InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
• InChIKey: BTBHLEZXCOBLCY-QGZVFWFLSA-N
• SMILES: CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C

Finerenone（Cat No.:I006795）is a non-steroidal mineralocorticoid receptor antagonist (MRA) used to treat chronic kidney disease (CKD) in patients with type 2 diabetes. By selectively blocking the mineralocorticoid receptor, finerenone reduces inflammation and fibrosis in the kidneys and heart, offering protective effects against CKD progression and cardiovascular complications. Unlike traditional MRAs, it has a lower risk of causing hyperkalemia. Finerenone provides an important therapeutic option for improving kidney function and reducing cardiovascular risk in diabetic patients with CKD, complementing standard treatments like ACE inhibitors or ARBs.